Aegerion Pharmaceuticals Announces First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Leerink Partners Cuts Price Target on Aegerion Pharma (AEGR) Following 1Q Miss and Guidance
May 17, 2016 6:50 AM EDTLeerink Partners maintained an Outperform rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and cut the price target to $6.00 (from $15.00), following the company's 1Q earnings report. AEGR reported revenue of $36M, missing consensus estimates of $43M. Management cut FY16 guidance at the midpoint from... More
